ClinicalTrials.gg
Active, not recruitingNCT06334133CATT1Updated Nov 2, 2026

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

A Phase 3 interventional study of Cadisegliatin 800 mg QD and Cadisegliatin 800 mg BID in Diabetes Mellitus, Type 1, sponsored by vTv Therapeutics. Active, not recruiting at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by vTv Therapeutics · Phase 3, Interventional, and Treatment

Updated Nov 2, 20261 site added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
222nd of 1,242
150 · median 40
Started
2024
with 62 others
Phase 3
147 of 1,458
10 open now
Primary completion
2027-04
later than 118 of 258 live
Registered
1,292nd of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 222nd largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 63 that started in 2024, is one of 147 in phase 3, reaches primary completion later than 118 of the 258 other live ones, and was the 1,292nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

Read the detailed description

Study TTP399-302 is a 26-week, Phase 3 trial designed to measure the relative efficacy of adjunctive treatment with cadisegliatin to reduce the incidence of Level 2 or Level 3 hypoglycemia in participants with Type 1 Diabetes Mellitus compared to placebo (insulin alone) over 26 weeks of continuous therapy.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals ≥18 years
  • Diagnosed T1DM with a minimum of 3 years since diagnosis
  • Has had at least 1 hypoglycemic event of Level 2 (glucose level \<54 mg/dL or \<3 mmol/L, [CGM or SMBG confirmed]) or Level 3 (defined as a severe hypoglycemia with altered mental state and/or physical status requiring assistance) in the last 2 months prior to Screening
  • value of \<9.5% at Screening
  • Is currently on CSII (closed-loop systems are prohibited) or is on MDI for at least 6 months prior to the Screening Visit and is willing to stay on same type of insulin treatment and the current mode of insulin administration (CSII or MDI injection treatments) for the duration of the study
  • Must have been on a CGM device for at least 3 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Has T2DM, monogenic diabetes, maturity-onset diabetes of the young, other unusual or rare forms of diabetes mellitus, or diabetes resulting from a secondary disease
  • Has been hospitalized for DKA within 3 months prior to Screening
  • Has uncontrolled hypothyroidism or hyperthyroidism
  • History of eating disorder within the last 2 years such as anorexia, bulimia, diabulimia or neglecting to give insulin to manipulate weight
  • Has an active or untreated , or has been in remission from malignancy for ≤5 years except well-treated basal cell or squamous cell skin cancer or cervical cancer in situ
  • Has used any of the following medications within the specified time periods - any non-insulin anti-diabetic therapies, e.g., sodium glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or pramlintide, alpha-glucosidase inhibitors, or glucose-dependent insulinotropic polypeptide agonists) or weight loss medications within 30 days prior to the Screening
  • Has used a hybrid closed-loop system (e.g., Medtronic 670G, Omnipod 5, or Tandem X2 with control IQ) or Do-It-Yourself looping within the last 30 days prior to the Screening Visit, and agrees to not start hybrid closed-loop systems or Do-It-Yourself looping during the study.
  • Has an estimated (eGFR) \<30 mL/min/1.73 m2 utilizing the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening
  • Has uncontrolled hypertension prior to Screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg QD

    The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 26-week treatment period. Insulin is adjunctive therapy.

    Drug: Cadisegliatin 800 mg QD

  • Experimental
    Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg BID

    The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 26-week treatment period. Insulin is adjunctive therapy.

    Drug: Cadisegliatin 800 mg BID

  • Placebo comparator
    Placebo: 26 Week Double Blind Treatment Period

    The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 26-week treatment period. Insulin is adjunctive therapy.

    Drug: Placebo

Interventions

  • Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.

    Also known as: TTP399

  • Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.

    Also known as: TTP399

  • DrugPlacebo

    Placebo (insulin alone)

06

What researchers measure

Primary outcomes

  1. Change in incidence of Level 2 or Level 3 hypoglycemia

    Number of events of Level 2 or Level 3 hypoglycemia in participants on cadisegliatin vs placebo.

    Time frame: 26 weeks

Secondary outcomes

  1. To assess the change in HbA1c

    Change from baseline in HbA1c in participants on cadisegliatin vs placebo.

    Time frame: 26 weeks

  2. To assess the effects of treatment on CGM-based metrics for glycemic control

    Change from baseline for time in, above or below target range of participants on cadisegliatin vs placebo

    Time frame: 26 weeks

  3. To assess the effects of treatment on the incidence of diabetic ketoacidosis

    Number of events of diabetic ketoacidosis participants on cadisegliatin vs placebo

    Time frame: 26 weeks

  4. To assess the effects of treatment on insulin dosing

    Change from baseline in average daily total insulin on cadisegliatin vs placebo

    Time frame: 18 weeks

  5. To assess the effects of treatment on body weight

    Change from baseline in mean body weight

    Time frame: 26 weeks

  6. To assess the incidence of treatment emergent adverse events

    Number of treatment emergent adverse events with cadisegliatin vs placebo

    Time frame: 26 weeks

  7. To assess the incidence of treatment emergent adverse events leading to discontinuation

    Number of treatment emergent adverse events leading to discontinuation with cadisegliatin vs placebo

    Time frame: 26 weeks

  8. To assess the incidence of adverse events of special interest

    Number of adverse events of special interests with cadisegliatin vs placebo

    Time frame: 26 weeks

07

Study locations

48 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Apr 2027, 34 months after the start.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 34 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 27, 2024
StartActual
Jun 14, 2024
Primary completionEst.
Apr 2027
CompletionEst.
May 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 5 sites removed
Show site
  • John Muir Physician Network Clinical Research Center · Concord, United States
Show 5 removed
  • 310 Clinical Research · Inglewood, United States
  • Paradigm Clinical Research · Boise, United States
  • John Muir Physician Network Clinical Research Center · Concord, United States
  • Citta Clinical Research, LLC · Spokane, United States
  • Velocity Clinical Research - Spokane · Spokane, United States
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 5 sites removed
    Show site
    • John Muir Physician Network Clinical Research Center · Concord, United States
    Show 5 removed
    • 310 Clinical Research · Inglewood, United States
    • Paradigm Clinical Research · Boise, United States
    • John Muir Physician Network Clinical Research Center · Concord, United States
    • Citta Clinical Research, LLC · Spokane, United States
    • Velocity Clinical Research - Spokane · Spokane, United States
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06334133
Lead sponsor
vTv Therapeutics
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Jun 14, 2024
Primary completion
Apr 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Thomas Strack, MD
study director · vTv Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTP399

Start the discussion